Study #2023-0504
A phase 1 clinical study of NXP900 in subjects with advanced cancers.
MD Anderson Study Status
Enrolling
Treatment Agent
NXP900
Description
The purpose of this dose escalation study is to evaluate the safety profile of escalating doses and dose schedules of NXP900.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumor
Study phase:
Phase I
Physician name:
Jordi Rodon Ahnert
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-833-642-1954
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.